"Single doses of cetuximab higher than 500 mg/m² have not been tested. There is no experience with overdosage in human clinical trials. "@en . . . . . "205923-56-4"@en . . . . "114 hrs"@en . . "Anti EGFR"@en . . "Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread."@en . . . . "Cetuximab"@en . . . . . "IMC-C225"@en . . . "approved"@en . . . . . "Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions."@en . . "Humans and other mammals"@en . "For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy."@en . " "@en . .